A new small molecule was seen to stimulate certain brain receptors, called NMDA receptors, and lessen abnormal brain epileptic activity…
Articles by Ana Pena, PhD
Daily treatment with Fintepla (a low-dose oral solution of fenfluramine), an investigational therapy by Zogenix, significantly reduces seizure…
The National Institute of Health and Care Excellence (NICE), an arm of U.K.’s public health system, favors use of…
Ovid Therapeutics‘ investigational treatment soticlestat (OV935/5/TAK935) was found to progressively reduce seizure frequency — by up to…
Sudden unexpected death in epilepsy (SUDEP)Â occurs more frequently during early evening and is significantly prevented by prolonged use of…
ZX008, an experimental therapy for Dravet syndrome, was found to be well-tolerated…
Cannabis-based experimental therapies currently under research, in particular Epidiolex, show significant promise to…
ZX008’s mechanism of action may avoid the side effects caused by other antiepileptic treatments, preclinical…
Treatment with topiramate (Topomax), lacosamide (Vimpat) and carbamazepine enabled a young woman with…
Researchers have identified two significant factors that can help predict cognitive outcomes in Dravet syndrome patients: Longer …